How do venture capital investors value formal Intellectual Property (IP) rights in connection with a decision to fund a technology or life sciences start-up? How do they conduct IP due diligence? How do investors and founders, post-funding, ensure their start-ups are pursuing an IP strategy that optimizes exit valuation for all? Perkins Coie partners Michael Glenn (Patent Prosecution) and Matt Oshinsky (Emerging Companies Venture Capital) will be joined alongside a seasoned venture capitalist to discuss these and other questions regarding safeguarding IP rights and maximizing the value of all technology development activities.